about
Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virusStructural basis of potent Zika–dengue virus antibody cross-neutralizationHumidity control as a strategy for lattice optimization applied to crystals of HLA-A*1101 complexed with variant peptides from dengue virusStructural Flexibility of the Macrophage Dengue Virus Receptor CLEC5AStructural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-ReactivityRecognition determinants of broadly neutralizing human antibodies against dengue virusesCross-reacting antibodies enhance dengue virus infection in humansCovalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitopeA complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections.Immunodominant T-cell responses to dengue virus NS3 are associated with DHF.Lectin switching during dengue virus infectionSensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells.A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?Erratum: Structural basis of potent Zika-dengue virus antibody cross-neutralization.Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response.Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.Longitudinal Analysis of Antibody Cross-Neutralization Following Zika and Dengue Virus Infection in Asia and the Americas.Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys.Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine
P50
Q24737245-E17F9BEC-B363-47F2-8380-ACC87DEBEC2EQ24740325-8A04E16D-277B-442D-A72E-4B138298B257Q27485892-7F3BE684-0930-4417-93FB-C2FC6AA70332Q27667825-5CA06A2F-ABA8-4288-A55E-AD417B43B9B5Q27678419-C218E65D-DF72-4EDC-8ED3-81D62FB0EE9BQ27697333-D750E97D-A8B0-45F2-B446-CAED5A5B46BAQ28281588-3E385487-869E-4F05-AA72-8FE5E73A22F9Q30250932-5DA4D054-1FAC-4350-99CF-E2560B417D37Q33381712-0E1DA6A9-65A0-43DF-A08C-D11F58DC964CQ34165624-438824B6-D135-42CE-A8BF-8CAC65609A19Q35000894-A9E19313-843E-4820-9689-6840120A4751Q35361219-C5A4E1B7-E02C-4BD3-B2C8-F9B1C5CF3F31Q35654743-38FEC7E5-0A92-4AF8-91DC-8F2254373ECCQ39263024-0B0B2156-4477-4037-8BB2-A73B2D597F97Q40053111-8B3AC728-3143-47D8-B396-FDB721BC9460Q41929032-94D21A75-DA5C-4A5E-AA05-81BF3744E8ACQ41929035-8B0D3A34-C4A0-4AB7-9E2D-18277283B423Q44669486-225CF21A-EF21-434E-87D3-394F73704867Q45342383-00DAFBE6-E88D-43A5-A52D-CC5B7A535F10Q54241921-FD22EE28-2512-4EBB-9E16-004EE58D2CA7Q55084408-4E014A46-7B03-4CCB-948B-C96C2B4081C7Q55387941-06F7F34F-62A7-4950-9DDF-5E80418167F8Q59353226-62B43D5A-ADD4-45BD-882F-B70174C076F4
P50
name
Wanwisa Dejnirattisai
@ast
Wanwisa Dejnirattisai
@en
Wanwisa Dejnirattisai
@es
Wanwisa Dejnirattisai
@nl
type
label
Wanwisa Dejnirattisai
@ast
Wanwisa Dejnirattisai
@en
Wanwisa Dejnirattisai
@es
Wanwisa Dejnirattisai
@nl
prefLabel
Wanwisa Dejnirattisai
@ast
Wanwisa Dejnirattisai
@en
Wanwisa Dejnirattisai
@es
Wanwisa Dejnirattisai
@nl